Filing Details
- Accession Number:
- 0000950170-25-032755
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-03-04 19:58:45
- Reporting Period:
- 2025-02-28
- Filing Date:
- 2025-03-04
- Accepted Time:
- 2025-03-04 19:58:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1817838 | Douglas Joseph Lyon | C/O Corcept Therapeutics Incorporated 101 Redwood Shores Parkway Redwood City CA 94065 | See Remarks | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2025-03-03 | 182 | $60.58 | 8,577 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2025-03-03 | 216 | $59.07 | 8,793 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2025-03-03 | 216 | $0.00 | 9,009 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2025-03-03 | 4,579 | $13.56 | 13,588 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-03-03 | 4,579 | $60.69 | 9,009 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Acquisiton | 2025-02-28 | 140,000 | $0.00 | 140,000 | $60.58 |
| Common Stock | Stock option (right to buy) | Disposition | 2025-03-03 | 4,579 | $0.00 | 4,579 | $13.56 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 140,000 | 2035-02-28 | No | 4 | A | Direct | |
| 91,992 | 2030-02-07 | No | 4 | M | Direct |
Footnotes
- These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- The closing price on February 28, 2025 was used to calculate the withholding obligation.
- Includes 1,232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025.
- In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.
- Fully exercisable.
Billionaire Hedge Funds
